Results 201 to 210 of about 27,986 (235)
Some of the next articles are maybe not open access.

TNFR2: A Novel Target for Cancer Immunotherapy

Trends in Molecular Medicine, 2017
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy but exhibit variable efficacy and relapse and can induce autoimmunity. Tumor necrosis factor (TNF) receptor 2 (TNFR2) is a signaling molecule found on the surface of a subset of potent regulatory T cells (Tregs) that can activate the proliferation of these cells through nuclear ...
Éva S, Vanamee, Denise L, Faustman
openaire   +2 more sources

Abstract 1814: Generation and validation of a novel humanized TNFR2 mouse model for the evaluation of therapeutic TNFR2 antibody

Cancer Research, 2021
Abstract Tumor necrosis factor receptor-2 (TNFR2) is a TNF receptor superfamily member which, unlike the well-characterized TNFR1, has been reported to have restricted expression in the immune system especially on suppressive regulatory T cell (Treg).
Xiaofeng Zhao   +8 more
openaire   +1 more source

Targeting the TNFR2 oncogene on tumor cells and tregs of the tumor microenvironment via dominant TNFR2 antagonism.

Journal of Clinical Oncology, 2017
106 Background: A major barrier to cancer immunotherapy is lack of selective inhibitors of the regulatory T cells (Tregs) of the cancer microenvironment and methods to directly kill tumors through novel surface oncogenes. Tumor necrosis factor receptor 2 (TNFR2) is a target protein with restricted expression on the most potent Tregs of the tumor ...
Denise L. Faustman   +11 more
openaire   +1 more source

Locking TNFR2 to kill ovarian cancer

Science, 2017
Cancer Immunotherapy The TNF (tumor necrosis factor) ligand family promotes tumor growth and progression. Torrey et al. developed an antibody that locks TNFR2, a TNF receptor found on immunosuppressive regulatory T cells and some tumor cells, in an inactive state (see the Focus by Chen and Oppenheim).
openaire   +2 more sources

Scutellarin suppresses the metastasis of triple-negative breast cancer via targeting TNFα/TNFR2-RUNX1-triggered G-CSF expression in endothelial cells.

Biochemical Pharmacology, 2023
Triple-negative breast cancer (TNBC) is heterogeneous and aggressive, with high vascularity and frequent metastasis. We have already found natural flavonoid scutellarin (SC) suppressed spontaneous TNBC metastasis via normalizing tumor vasculature in vivo.
Xi-Yu Mei   +6 more
semanticscholar   +1 more source

TNFR2-targeting peptide for cancer immunotherapy

The Journal of Immunology, 2023
Abstract There is compelling evidence that tumor necrosis factor receptor type II (TNFR2) is preferentially expressed by highly immunosuppressive CD4+Foxp3+ regulatory T cells (Tregs), especially those present in tumor-infiltrating lymphocytes (TILs).
Xin Chen, Ping Liao, Zhonghao Chen
openaire   +1 more source

Abstract A056: TNFR2 is a novel marker of exhaustion and TNFR2 blockade improves subcutaneous tumor control

Cancer Immunology Research
Abstract Checkpoint inhibitors have been very successful in various tumors, including melanoma and lung cancer. However, these treatments have failed in other tumors, including pancreatic cancer and glioblastoma. Approaches harnessing the immune response are hindered by multiple factors, including T cell exhaustion. Exhausted T cells are
Alexandra Hoyt-Miggelbrink   +12 more
openaire   +1 more source

TNFR2 Antagonistic Antibody Induces the Death of Tumor Infiltrating CD4+Foxp3+ Regulatory T Cells

Cellular Oncology (Dordrecht), 2023
De Yang   +2 more
exaly  

Home - About - Disclaimer - Privacy